Gallium-68 PSMA PET scanning “is a game changer” in prostate cancer

The “game changer” statement above comes from an independent review of the potential value of gallium-86-labeled prostate-specific molecular antigen (68Ga PSMA) PET scanning in the evaluation of selected men with prostate cancer. … READ MORE …

Who really needs to be given a prostate biopsy?

A newly published article in Reviews in Urology argues that, on economic grounds alone, the majority of patients thought to be at risk for prostate cancer should have a 4KScore test prior to them being given a biopsy since this test can rule out the need for biopsies with a high degree of accuracy. … READ MORE …

The evolution of evaluation of risk for clinically significant prostate cancer

Whatever one may happen to think about the value of the PSA test, we all know that it is very bad at actually telling a doctor or a patient if that patient is at real risk for clinically significant prostate cancer. So, from that perspective … READ MORE …

The optimization of risk assessment for management of prostate cancer

According to information from the Medical University of Vienna (in Austria) and Vienna General Hospital, researchers at these centers have been developing what they believe to be a smarter set of strategies for assessing prostate cancer risk and subsequent treatment, when this is needed. … READ MORE …

Test your knowledge on the diagnosis and staging of prostate cancer

Support group leaders and other prostate cancer educators may wish to test their knowledge on the diagnosis and staging of prostate cancer by reading through the set of 29 slides prepared by Kleynberg and Gross and just made available on the Medscape web site.

Can a single, specialized MRI scan replace bone and CT scans for men with high-risk prostate cancer?

A recent paper by a team of Belgian researchers has suggested that diffusion-weighted. whole-body magnetic resonance imaging (DWWBMRI) may be able to replace historic forms of imaging — bone scans and contrast-enhanced CT scans and/or standard MRIs of the pelvis in the work-up of men at high risk for metastatic prostate cancer. … READ MORE …

Delayed follow-up care of men with a high PSA found to be common

For any man with a first-time PSA level > 10 ng/ml, there is significant risk for prostate cancer, and early follow-up care — including a repeat PSA test and potentially a biopsy — is probably a priority unless the patient has a life expectancy of 10 years or less. … READ MORE …